Anti-CD3-anti-EGFR monoclonal antibody

Drug Profile

Anti-CD3-anti-EGFR monoclonal antibody

Alternative Names: Bispecific monoclonal antibody M26.1; Bispecific monoclonal antibody OKT3-EGFR

Latest Information Update: 07 Aug 1998

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Epidermal growth factor receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Aug 1998 Profile reviewed
  • 07 Aug 1998 No-Development-Reported for Cancer in Italy (Unknown route)
  • 07 Aug 1998 No-Development-Reported for Cancer in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top